The VA Medicinal Cannabis Research Act is back in Congress, and this version tells the VA to study the cannabis veterans actually use: whole plant material and extracts with varying THC to CBD ratios, not just isolated lab compounds. Reps. Lou Correa and Jack Bergman reintroduced the bipartisan bill with backing from IAVA and VFW, and if it passes the VA starts a large observational study within 180 days.
Why does the whole plant requirement change everything?
Most federal cannabinoid research studies isolated compounds or pharma formulations like Epidiolex or Marinol. Those products look nothing like what veterans buy at dispensaries or grow themselves. A single synthetic molecule tells you something, but it does not tell you how a veteran using high THC flower or a balanced tincture experiences relief, or risk.
By writing whole plant raw material, extracts, and multiple cannabinoid ratios into the bill text, Congress is setting up findings that map to real world use. For an industry that has argued for years that isolated compound studies undersell the plant, this is Congress writing our argument into federal law. I have made this case on stage and in print for years: study the plant people actually consume, or stop pretending the results apply to them.
What will the VA actually measure?
The bill does not just ask whether cannabis “works.” The observational study tracks changes in opioid use, benzodiazepine use, alcohol consumption, sleep quality, pain intensity, mood, anxiety, social functioning, agitation, suicidal ideation, and newly developed or worsened mental health conditions. Both positive and negative outcomes.
That balance is the smartest part of the design. Past versions drew pushback from VA officials who worried the mandate was rigid advocacy dressed as science. Building negative outcomes into the study from day one makes that objection much harder to sustain. I respect legislation that is willing to find bad news. It is the only kind worth trusting.
Why did this bill die before, and what is different now?
Versions of this bill cleared House committees in 2018, 2020, and 2021, and a Senate companion reached the floor before dying on a procedural vote. None became law. This version drops the old mandate that studies include at least seven cannabis varieties, and it gives the VA real discretion: within 90 days of finishing the observational phase, the agency reports whether it can run clinical trials to FDA standards, and trials only start if the VA says it is ready. The VA can also terminate trials early for excessive risk.
Those changes are aimed squarely at the agency objections that sank momentum last time. It still has to get through hearings and markup, so nothing is guaranteed. But this is the most passable version yet, and it follows the earlier Congress pushing the VA to study medical marijuana for veterans with PTSD that I covered here on the site.
The arc from folk remedy to precision product is the same story I traced in how RSO evolved from syringes to tablets. You can browse the full medical cannabis collection for the studies and product stories behind this debate.
Frequently Asked Questions
- What is the VA Medicinal Cannabis Research Act? It is a bipartisan bill reintroduced by Reps. Lou Correa (Democrat, California) and Jack Bergman (Republican, Michigan) directing the VA Office of Research and Development to run a large scale observational study on veterans with chronic pain and PTSD, examining how cannabis use correlates with changes across a wide set of health outcomes.
- Who is backing the bill? Correa and Bergman are the sponsors, a California Democrat and Michigan Republican pairing built around veteran health rather than legalization politics. IAVA CEO Kyleanne Hunter called it long overdue, and VFW’s Pat Murray echoed the support, noting members already credit cannabis with managing service connected conditions.
- Why does the whole plant language matter? Because most existing research uses isolated compounds while veterans use flower, vapes, and tinctures. Requiring whole plant raw material, extracts, and varying THC to CBD ratios means the findings will map to real world use instead of lab conditions nobody recognizes.
- Has Congress tried this before? Yes. Versions cleared House committee votes in 2018, 2020, and 2021, and a Senate companion advanced to the floor before procedural objections killed it. No version has ever become law.
- When would veterans see results? If passed, the VA has 180 days to start an 18 month observational study, then 90 days to report on clinical trial readiness. Trials would begin within 180 days of that report only if the VA says it is ready. Real answers are years out, which is exactly why starting now matters.
Source: Beard Bros Pharms on the reintroduction of the VA Medicinal Cannabis Research Act